<DOC>
	<DOCNO>NCT00274222</DOCNO>
	<brief_summary>This study design evaluate hypothesis nebulized budesonide ) might alternative systemic corticosteroid ( SC ) treatment patient acute exacerbation COPD ( AECOPD ) .</brief_summary>
	<brief_title>The Role Nebulized Budesonide Treatment Acute Exacerbations COPD</brief_title>
	<detailed_description>Patients , hospitalize AECOPD , randomize three group . Group I receive bronchodilator treatment ( BDT ) , Group II receive SC ( 40 mg prednisolon ) plus BDT , Group III receive nebulized budesonide ( NB ) ( 1500 mcg qid ) plus BDT . Improvement rate multiple parameter 10-day hospitalization , acute exacerbation re-hospitalization rate within one-month discharge compare group .</detailed_description>
	<mesh_term>Budesonide</mesh_term>
	<criteria>COPD patient admit pulmonary department acute exacerbation prospectively enrol study COPD patient hospitalize specific reason like pneumonia , pulmonary embolus , congestive heart failure , pneumothorax etc . cause acute exacerbation , patient risk imminent respiratory failure require mechanical ventilation direct admission ICU exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>COPD , nebulized budesonide , systemic corticosteroid</keyword>
</DOC>